Suppr超能文献

加拿大西部基于药房的筛查项目,用于在“婴儿潮一代”人群中检测丙型肝炎。

Pharmacy-based screening program to detect hepatitis C in 'baby-boomer' cohorts in western Canada.

作者信息

Chiew Brandon A, Fong Anita Yp, Cosgrove Linh T, Mohajerani Seyed Amir, Ramji Alnoor, Lee Samuel S

机构信息

Liver Unit, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.

London Drugs, 12831 Horseshoe Place, Richmond, British Columbia, Canada.

出版信息

Can Liver J. 2023 Dec 20;6(4):388-394. doi: 10.3138/canlivj-2023-0005. eCollection 2023 Dec.

Abstract

BACKGROUND

The estimated prevalence of hepatitis C virus (HCV) in Canada is approximately 1.0%. However, the number of individuals living with HCV but unaware of it is estimated to be 30%-44%. Increased screening programs that are accessible, effective, and feasible are important to ensure treatment and meet WHO elimination goals. We implemented an HCV point of care test (POCT) program in community pharmacies to examine the effectiveness and feasibility in screening.

METHODS

Twenty two London Drugs pharmacies in British Columbia and Alberta implemented an HCV POC screening program using OraQuick rapid antibody tests. Consenting patients filled out a 10-question screening questionnaire to examine risk factors. The participants then were tested using the POCT. While waiting for the test (20 minutes), patients were educated on HCV and treatment options.

RESULTS

Three hundred seventy-one participants underwent HCV screening. The most common HCV risk factor was being born between 1945 and 1975 (baby boomer) (93% of cohort), while the second most common was having a tattoo or body piercing (22%). Seven people (2%) tested positive; four were HCV-RNA PCR-positive and were treated, whereas the PCR status of three was unknown as they were lost to follow-up or not tested.

CONCLUSIONS

Pharmacy-based POCT was shown to be effective and feasible in the western Canadian context, especially for baby boomers. Sustainable funding for pharmacy screening programs may be considered nationwide to identify HCV-infected persons and help meet elimination goals.

摘要

背景

加拿大丙型肝炎病毒(HCV)的估计患病率约为1.0%。然而,估计有30%-44%的HCV感染者并不知道自己感染。增加可及、有效且可行的筛查项目对于确保治疗和实现世界卫生组织的消除目标至关重要。我们在社区药房实施了一项HCV即时检验(POCT)项目,以检验筛查的有效性和可行性。

方法

不列颠哥伦比亚省和艾伯塔省的22家伦敦药店实施了一项使用奥奎克快速抗体检测的HCV即时检验筛查项目。同意参与的患者填写一份包含10个问题的筛查问卷,以检查风险因素。然后使用即时检验对参与者进行检测。在等待检测结果(20分钟)期间,对患者进行HCV及治疗选择方面的教育。

结果

371名参与者接受了HCV筛查。最常见的HCV风险因素是出生于1945年至1975年之间(婴儿潮一代)(占队列的93%),第二常见的是有纹身或穿孔(22%)。7人(2%)检测呈阳性;4人HCV-RNA PCR检测呈阳性并接受了治疗,而另外3人的PCR检测结果未知,因为他们失访或未进行检测。

结论

在加拿大西部的背景下,基于药房的即时检验被证明是有效且可行的,尤其是对婴儿潮一代。可考虑在全国范围内为药房筛查项目提供可持续资金,以识别HCV感染者并帮助实现消除目标。

相似文献

1
Pharmacy-based screening program to detect hepatitis C in 'baby-boomer' cohorts in western Canada.
Can Liver J. 2023 Dec 20;6(4):388-394. doi: 10.3138/canlivj-2023-0005. eCollection 2023 Dec.
2
Primary Care Perspectives on Hepatitis C Virus Screening, Diagnosis and Linking Patients to Appropriate Care.
Am J Med. 2017 Feb;130(2):S1-S2. doi: 10.1016/j.amjmed.2017.01.001. Epub 2017 Jan 11.
3
Patient awareness, willingness, and barriers to point-of-care hepatitis C screening in community pharmacy.
J Am Pharm Assoc (2003). 2018 Jul-Aug;58(4S):S69-S72.e1. doi: 10.1016/j.japh.2018.04.031.
4
Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA.
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1451-1458.e4. doi: 10.1016/j.cgh.2020.07.058. Epub 2020 Aug 4.
5
Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department.
Hepatology. 2015 Mar;61(3):776-82. doi: 10.1002/hep.27410. Epub 2015 Jan 28.
6
Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: A pilot project.
J Am Pharm Assoc (2003). 2017 Jul-Aug;57(4):510-515.e2. doi: 10.1016/j.japh.2017.04.463. Epub 2017 Jun 9.
8
'': Barriers to pharmacy-based identification and treatment of hepatitis C in Victoria, Canada.
Can Liver J. 2024 May 8;7(2):257-272. doi: 10.3138/canlivj-2023-0016. eCollection 2024 May.
9
Time and motion study of hepatitis C virus point-of-care testing in community pharmacies.
J Am Pharm Assoc (2003). 2023 Jan-Feb;63(1):435-439. doi: 10.1016/j.japh.2022.11.002. Epub 2022 Nov 5.

本文引用的文献

1
National Hepatitis C estimates: Incidence, prevalence, undiagnosed proportion and treatment, Canada, 2019.
Can Commun Dis Rep. 2022 Nov 3;48(11-12):540-549. doi: 10.14745/ccdr.v48i1112a07.
2
Timing of elimination of hepatitis C virus in Canada's provinces.
Can Liver J. 2022 Nov 7;5(4):493-506. doi: 10.3138/canlivj-2022-0003. eCollection 2022 Nov.
3
Treating hepatitis C during the COVID-19 pandemic in Alberta.
Can Liver J. 2021 Apr 29;4(2):79-81. doi: 10.3138/canlivj-2021-0007. eCollection 2021 Spring.
4
ECHO+: Improving access to hepatitis C care within Indigenous communities in Alberta, Canada.
Can Liver J. 2022 May 9;5(2):113-123. doi: 10.3138/canlivj-2021-0027. eCollection 2022 Spring.
5
Achieving HCV micro-elimination in rural communities.
Can Liver J. 2021 Feb 24;4(1):1-3. doi: 10.3138/canlivj-2020-0022. eCollection 2021 Winter.
6
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada.
Lancet Gastroenterol Hepatol. 2022 Jul;7(7):590-592. doi: 10.1016/S2468-1253(22)00129-7.
9
Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs.
Open Forum Infect Dis. 2020 May 26;7(6):ofaa196. doi: 10.1093/ofid/ofaa196. eCollection 2020 Jun.
10
Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada.
Int J Drug Policy. 2020 Jun;80:102755. doi: 10.1016/j.drugpo.2020.102755. Epub 2020 May 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验